<div id="readability-page-1"><p>Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Oncology Institute today and set a price target of $8.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, LeBoyer is an analyst with an average return of <span>-9.2%</span> and a 28.57% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Gyre Therapeutics, Unicycive Therapeutics, and Ocugen.</p> <p>In addition to Noble Financial, Oncology Institute also received a Buy from BTIG’s David Larsen in a report issued yesterday. However, today, TR | OpenAI – 4o reiterated a Hold rating on Oncology Institute (NASDAQ: TOI).</p></div>

<p>Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Oncology Institute with a price target of $8.00. Despite LeBoyer's average return of -9.2% and a 28.57% success rate, Oncology Institute also received a Buy rating from BTIG's David Larsen. However, TR | OpenAI – 4o maintained a Hold rating on the stock.</p>

Noble Financial Remains a Buy on Oncology Institute (TOI)